BRPI1013774A2 - "quimioterapia de neoplasma hematopoiético." - Google Patents

"quimioterapia de neoplasma hematopoiético."

Info

Publication number
BRPI1013774A2
BRPI1013774A2 BRPI1013774A BRPI1013774A BRPI1013774A2 BR PI1013774 A2 BRPI1013774 A2 BR PI1013774A2 BR PI1013774 A BRPI1013774 A BR PI1013774A BR PI1013774 A BRPI1013774 A BR PI1013774A BR PI1013774 A2 BRPI1013774 A2 BR PI1013774A2
Authority
BR
Brazil
Prior art keywords
chemotherapy
hematopoietic neoplasm
neoplasm
hematopoietic
neoplasm chemotherapy
Prior art date
Application number
BRPI1013774A
Other languages
English (en)
Portuguese (pt)
Inventor
Marcio Chedid
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1013774(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI1013774A2 publication Critical patent/BRPI1013774A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI1013774A 2009-04-14 2010-04-08 "quimioterapia de neoplasma hematopoiético." BRPI1013774A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16909409P 2009-04-14 2009-04-14
PCT/US2010/030315 WO2010120614A1 (en) 2009-04-14 2010-04-08 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia

Publications (1)

Publication Number Publication Date
BRPI1013774A2 true BRPI1013774A2 (pt) 2016-04-05

Family

ID=42174602

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013774A BRPI1013774A2 (pt) 2009-04-14 2010-04-08 "quimioterapia de neoplasma hematopoiético."

Country Status (23)

Country Link
US (2) US8802668B2 (OSRAM)
EP (1) EP2419106A1 (OSRAM)
JP (1) JP5699129B2 (OSRAM)
KR (1) KR101290509B1 (OSRAM)
CN (1) CN102395372B (OSRAM)
AU (1) AU2010236747B2 (OSRAM)
BR (1) BRPI1013774A2 (OSRAM)
CA (1) CA2758473C (OSRAM)
CL (1) CL2011002531A1 (OSRAM)
DO (1) DOP2011000312A (OSRAM)
EA (1) EA018933B1 (OSRAM)
EC (1) ECSP11011403A (OSRAM)
IL (1) IL215107A0 (OSRAM)
MA (1) MA33184B1 (OSRAM)
MX (1) MX2011010937A (OSRAM)
MY (1) MY157218A (OSRAM)
NZ (1) NZ595413A (OSRAM)
PE (1) PE20120772A1 (OSRAM)
SG (1) SG175207A1 (OSRAM)
TN (1) TN2011000500A1 (OSRAM)
TW (1) TWI453022B (OSRAM)
UA (1) UA103792C2 (OSRAM)
WO (1) WO2010120614A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120772A1 (es) 2009-04-14 2012-06-27 Lilly Co Eli Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
WO2012125787A1 (en) 2011-03-17 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFβ AND RUNX1 PROTEINS
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
CN102887896B (zh) * 2012-10-26 2015-11-18 南京工业大学 一种2-（咪唑并[1,2-a]吡啶-3-基）乙腈的制备方法
WO2014090398A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
CN104945436B (zh) * 2015-07-09 2017-02-08 山东罗欣药业集团股份有限公司 一种米诺膦酸的制备方法
KR101694063B1 (ko) 2015-10-12 2017-01-17 전남대학교병원 Ｂｉｏ 화합물을 함유하는 심혈관질환의 치료용 조성물
WO2018083481A1 (en) 2016-11-03 2018-05-11 Ucl Business Plc Cancer therapy
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
KR100974770B1 (ko) * 2002-03-05 2010-08-06 일라이 릴리 앤드 캄파니 키나제 억제제로서의 퓨린 유도체
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
ATE535241T1 (de) 2007-12-05 2011-12-15 Univ Mainz Johannes Gutenberg Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
PE20120772A1 (es) 2009-04-14 2012-06-27 Lilly Co Eli Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia

Also Published As

Publication number Publication date
CA2758473C (en) 2013-12-17
JP2012524089A (ja) 2012-10-11
US8802668B2 (en) 2014-08-12
CN102395372B (zh) 2014-07-02
MY157218A (en) 2016-05-13
ECSP11011403A (es) 2011-11-30
TW201105328A (en) 2011-02-16
CA2758473A1 (en) 2010-10-21
CL2011002531A1 (es) 2012-06-01
KR20120004447A (ko) 2012-01-12
EP2419106A1 (en) 2012-02-22
IL215107A0 (en) 2011-12-29
JP5699129B2 (ja) 2015-04-08
SG175207A1 (en) 2011-11-28
EA201171243A1 (ru) 2012-03-30
AU2010236747B2 (en) 2012-11-08
PE20120772A1 (es) 2012-06-27
MX2011010937A (es) 2011-11-02
AU2010236747A1 (en) 2011-10-06
MA33184B1 (fr) 2012-04-02
UA103792C2 (uk) 2013-11-25
WO2010120614A1 (en) 2010-10-21
CN102395372A (zh) 2012-03-28
TN2011000500A1 (en) 2013-05-24
TWI453022B (zh) 2014-09-21
US20100261712A1 (en) 2010-10-14
US9044487B2 (en) 2015-06-02
DOP2011000312A (es) 2011-10-31
EA018933B1 (ru) 2013-11-29
NZ595413A (en) 2013-05-31
US20140235621A1 (en) 2014-08-21
KR101290509B1 (ko) 2013-07-26

Similar Documents

Publication Publication Date Title
BRPI1013774A2 (pt) "quimioterapia de neoplasma hematopoiético."
BRPI0924494A2 (pt) "refrigerador."
BRPI1010301A2 (pt) composição.
BRPI0922005A2 (pt) composições antiespumantes.
BR112013008464A2 (pt) composição de revestimento.
BRPI1014207A2 (pt) "trasmissão."
BR112013019327A2 (pt) composto, e, composição.
FR2959547B1 (fr) Poulie de decouplage.
JP2011229212A5 (OSRAM)
IT1397416B1 (it) Tavolo con base telescopica-basculante.
BR112013030897A2 (pt) composição.
IT1403920B1 (it) Composti fotosensibilizzanti "metal free".
JP2013005646A5 (OSRAM)
IT1400435B1 (it) Elevatore per munizioni.
BRPI1013798A2 (pt) composições de poliolefinas.
BRPI1014244A2 (pt) composto de polipropileno-talco estabilizado.
IT1401437B1 (it) Collarino di serraggio.
IT1399443B1 (it) Indumento intimo.
BR112014029893A2 (pt) encaixe de tubulação.
IT1406067B1 (it) Composizioni eudermiche.
IT1401345B1 (it) Bomboletta.
IT1397467B1 (it) Tornio.
BR112012033480A2 (pt) composições de etanol.
IT1400533B1 (it) Portale di autolavaggio perfezionato.
IT1403336B1 (it) Cassettiera.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]